These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33767486)

  • 21. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France.
    Bezin J; Pariente A; Lassalle R; Dureau-Pournin C; Abouelfath A; Robinson P; Moore N; Droz-Perroteau C; Fourrier-Reglat A
    Eur J Clin Pharmacol; 2014 Apr; 70(4):429-36. PubMed ID: 24271648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland.
    Welker J; Auer R; Gencer B; Muller O; Cornuz J; Matter CM; Mach F; Windecker S; Rodondi N; Nanchen D
    Swiss Med Wkly; 2016; 146():w14275. PubMed ID: 26859223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Underuse of beta-blockers by patients with COPD and co-morbid acute coronary syndrome: A nationwide follow-up study in New Zealand.
    Parkin L; Quon J; Sharples K; Barson D; Dummer J
    Respirology; 2020 Feb; 25(2):173-182. PubMed ID: 31401813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge.
    Jin H; Tang C; Wei Q; Chen L; Sun Q; Ma G; Liu N
    BMC Cardiovasc Disord; 2014 Sep; 14():127. PubMed ID: 25252927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event.
    Thornley S; Marshall R; Chan WC; Kerr A; Harrison J; Jackson G; Crengle S; Wright C; Wells S; Jackson R
    Eur J Prev Cardiol; 2012 Jun; 19(3):349-57. PubMed ID: 21450568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 27. Medication burden in patients with acute coronary syndromes.
    Wright EA; Steinhubl SR; Jones JB; Barua P; Yan X; Van Loan R; Frederick G; Bhandary D; Cobden D
    Am J Manag Care; 2017 Apr; 23(4):e106-e112. PubMed ID: 28554213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9).
    Kerr A; Williams MJ; White H; Doughty R; Nunn C; Devlin G; Grey C; Lee M; Flynn C; Rhodes M; Sutherland K; Wells S; Jackson R; Stewart R
    N Z Med J; 2016 Aug; 129(1439):23-36. PubMed ID: 27507719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-hospital prescriptions of secondary-prevention medications for post-acute coronary syndrome patients in South Korea
.
    Kang HB; Choi M; Yoon SG; Cho YS; Je NK
    Int J Clin Pharmacol Ther; 2018 Jan; 56(1):1-11. PubMed ID: 29168689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trends in length of stay following acute coronary syndrome hospitalisation in New Zealand 2006-2016: ANZACS-QI 32 study.
    Wang TKM; Grey C; Jiang Y; Jackson R; Kerr A
    N Z Med J; 2020 Jan; 133(1508):29-42. PubMed ID: 31945041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012.
    Elliott JM; Wang TK; Gamble GD; Williams MJ; Matsis P; Troughton R; Hamer A; Devlin G; Mann S; Richards M; French JK; White HD; Ellis CJ
    N Z Med J; 2017 Apr; 130(1453):17-28. PubMed ID: 28384143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic underutilisation of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function.
    Khedri M; Szummer K; Carrero JJ; Jernberg T; Evans M; Jacobson SH; Spaak J
    Eur J Prev Cardiol; 2017 May; 24(7):724-734. PubMed ID: 28195517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reinforcement of patient education improved physicians' adherence to guideline-recommended medical therapy after acute coronary syndrome.
    Lee CK; Lai CL; Lee MH; Su FY; Yeh TS; Cheng LY; Hsieh MY; Wu YW; Liu YB; Wu CC
    PLoS One; 2019; 14(6):e0217444. PubMed ID: 31170175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery.
    Looi KL; Chow KL; Looi JL; Lee M; Halliday S; White H; Ellis C
    N Z Med J; 2011 Sep; 124(1343):18-27. PubMed ID: 21964009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and type of bleeding complications early and late after acute coronary syndrome admission in a New Zealand cohort (ANZACS-QI-7).
    Voss WB; Lee M; Devlin GP; Kerr AJ
    N Z Med J; 2016 Jul; 129(1437):27-38. PubMed ID: 27362596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrasting Trends in Acute Coronary Syndrome Hospitalisation and Coronary Revascularisation in New Zealand 2006-2016: A National Data Linkage Study (ANZACS-QI 27).
    Wang TKM; Grey C; Jiang Y; Jackson R; Kerr A
    Heart Lung Circ; 2020 Sep; 29(9):1375-1385. PubMed ID: 31974025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
    BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome.
    Wang CY; Lin ZF; Lee CM; Tsai YW; Huang TY; Shen LJ; Hsiao FY
    Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):229-238. PubMed ID: 28067454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial.
    Xavier D; Gupta R; Kamath D; Sigamani A; Devereaux PJ; George N; Joshi R; Pogue J; Pais P; Yusuf S
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):244-253. PubMed ID: 26857999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.